SEC EDGARAUG 281 min read$TEM

LEFKOFSKY ERIC P sold $828K of TEM (indirect holdings)

LEFKOFSKY ERIC P (CEO and Chairman) sold 11,848 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $69.87 ($69.83–$70.58, $0.83M total) across 2 trades on 2026-08-25 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · LEFKOFSKY ERIC P

Published Aug 28, 2026, 12:28 AM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 28, 2026, 12:34 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$TEM

Bearish

medium confidence

Mentioned

$TEM

Relevance

4/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$TEMBearishLow

Why it matters

The disclosed sale provides fresh data on insider sentiment, useful for short‑term traders.

Market read

Primary insider sale news; modest materiality but relevant for short‑term price action.

What to watch

The CEO retains a sizable stake (150,000 shares) and the sale was pre‑planned, which may mitigate concerns.

Relevance 4/10Novelty 6/10Timing: filing disclosed today

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan allows pre‑arranged sales.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TEMBearishMedium confidence

Context

CEO Eric Lefkofsky sold 11,848 shares for $828K via a 10b5-1 plan, reducing his stake to 150,000 shares.

Expected impact

Potential modest downside pressure over the next few days.

Evidence & confidence

A $828K sale by the CEO is material for a mid‑cap biotech, but the amount is modest relative to market cap.

Market effects

Sector

May raise questions about Tempus AI's near‑term outlook among biotech investors.

Regional

Limited to U.S. biotech sector; no broader regional effect.

Global

Minimal global impact beyond the company's share price.

Counterpoint

What could challenge this read

The sale could be routine under a pre‑arranged plan and not reflect negative sentiment.

Key entities

Company
Tempus AI, Inc.
Biotech firm focused on AI‑driven clinical data platforms.
Executive
Eric Lefkofsky
CEO and Chairman of Tempus AI.

Read at source ← All news

AUG 28

$TSLALow

Cathie Wood Invested Roughly $1.4 Billion of Ark Invest's Flagship ETF in Just 3 Artificial Intelligence (AI) Stocks

Ark Invest's ARK Innovation ETF, managed by Cathie Wood, allocated $1.4B to three AI-related stocks: Tesla (TSLA) with a $595M position and $2,600 price target by 2029, Tempus AI (TEM) with a $402M position, and SpaceX (SPCX) with a $378M position. The ETF has $6.42B in assets under management.

aol.com3 min

AUG 27

$TEMMedAI 9/10

Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

Tempus AI (TEM) shares rose after Moderna and Merck reported positive Phase 3 trial results for a personalized cancer therapy, validating Personalis' sequencing technology. Tempus agreed to acquire Personalis for $1.5B, with the deal pending. Personalis' technology is distinct from the main target of the acquisition, NeXT Personal, a tumor-informed molecular residual disease test. Tempus reported 9,000 MRD tests in Q2, while Personalis generated $22.357M in revenue and delivered 10,384 clinical

insidermonkey.com3 min

AUG 24

$PSNLMed

Personalis falls amid a downgrade as competive bid appears unlikely

Personalis Inc. (PSNL) fell 6% after Craig-Hallum downgraded it to hold from buy, citing an unlikely higher bid than its announced sale to Tempus AI (TEM). Tempus shares also dropped 7.2%.

seekingalpha.com1 min

AUG 24

$TEMMedAI 8/10

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

Tempus AI, Inc. (NASDAQ: TEM) received FDA clearance for its AI product, Tempus ECG-PH, designed to detect signs of pulmonary hypertension from standard ECGs. This is the third FDA-cleared cardiovascular device in Tempus' portfolio, aiming to help clinicians identify at-risk patients earlier. The product analyzes ECG data but is not intended for standalone diagnosis.

biospace.com2 min

AUG 23

$TEMHighAI 8/10

Why Tempus AI Skyrocketed This Week

Tempus AI (TEM) shares rose 39.5% this week after Merck and Moderna reported positive Phase 3 trial data for their cancer vaccine, which uses technology from Personalis, a company Tempus is acquiring. Tempus's market cap is $13B, and its stock is still down about 10% over the past year. The acquisition is expected to close late 2024 or early 2027.

fool.com2 min

AUG 22

$PSNLHighAI 8/10

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Outlook

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.

stockstotrade.com3 min